Based on the development of a number of small-molecule and antibody antagonists to prevent receptor dimerization, current research is thereby focused on abrogating binding to CSF1 and activation of signaling, decreasing TAM infiltration and augmenting the effect of antitumor immune in the tumor [70, 71]. The gene discussed is CSF1; the disease is neoplasm.